929O_PR ICON8: A GCIG phase III randomised trial evaluating weekly dose- dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: results of primary progression- free survival (PFS) analysis

2.50
Hdl Handle:
http://hdl.handle.net/10541/620638
Title:
929O_PR ICON8: A GCIG phase III randomised trial evaluating weekly dose- dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: results of primary progression- free survival (PFS) analysis
Authors:
Clamp, Andrew R; McNeish, I; Dean, A; Gallardo, D; Weon-Kim, J; O'Donnell, D; Hook, J; Coyle, C; Blagden, S; Brenton, J; Naik, R; Perren, T; Sundar, S; Cook, A; James, E; Swart, A; Stenning, S; Kaplan, R; Ledermann, J
Affiliation:
Medical Oncology, The Christie NHS Foundation Trust and University of Manchester, Manchester, UK
Citation:
929O_PRICON8: A GCIG phase III randomised trial evaluating weekly dose- dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: results of primary progression- free survival (PFS) analysis 2017, 28(suppl_5): Ann Oncol
Journal:
Annals of Oncology
Issue Date:
Sep-2017
URI:
http://hdl.handle.net/10541/620638
DOI:
10.1093/annonc/mdx440.039
Additional Links:
http://academic.oup.com/annonc/article/doi/10.1093/annonc/mdx440.039/4109951/929OPRICON8-A-GCIG-phase-III-randomised-trial
Type:
Meetings and Proceedings
Language:
en
ISSN:
0923-7534; 1569-8041
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorClamp, Andrew Ren
dc.contributor.authorMcNeish, Ien
dc.contributor.authorDean, Aen
dc.contributor.authorGallardo, Den
dc.contributor.authorWeon-Kim, Jen
dc.contributor.authorO'Donnell, Den
dc.contributor.authorHook, Jen
dc.contributor.authorCoyle, Cen
dc.contributor.authorBlagden, Sen
dc.contributor.authorBrenton, Jen
dc.contributor.authorNaik, Ren
dc.contributor.authorPerren, Ten
dc.contributor.authorSundar, Sen
dc.contributor.authorCook, Aen
dc.contributor.authorJames, Een
dc.contributor.authorSwart, Aen
dc.contributor.authorStenning, Sen
dc.contributor.authorKaplan, Ren
dc.contributor.authorLedermann, Jen
dc.date.accessioned2017-11-21T21:33:02Z-
dc.date.available2017-11-21T21:33:02Z-
dc.date.issued2017-09-
dc.identifier.citation929O_PRICON8: A GCIG phase III randomised trial evaluating weekly dose- dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: results of primary progression- free survival (PFS) analysis 2017, 28(suppl_5): Ann Oncolen
dc.identifier.issn0923-7534-
dc.identifier.issn1569-8041-
dc.identifier.doi10.1093/annonc/mdx440.039-
dc.identifier.urihttp://hdl.handle.net/10541/620638-
dc.language.isoenen
dc.relation.urlhttp://academic.oup.com/annonc/article/doi/10.1093/annonc/mdx440.039/4109951/929OPRICON8-A-GCIG-phase-III-randomised-trialen
dc.rightsArchived with thanks to Annals of Oncologyen
dc.title929O_PR ICON8: A GCIG phase III randomised trial evaluating weekly dose- dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: results of primary progression- free survival (PFS) analysisen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentMedical Oncology, The Christie NHS Foundation Trust and University of Manchester, Manchester, UKen
dc.identifier.journalAnnals of Oncologyen
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.